Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

Mostrar otras versiones (1)

BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway reactivation through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) si...

Descripción completa

Detalles Bibliográficos
Autores principales: Girotti, Maria Romina, Lopes, Filipa, Preece, Natasha, Niculescu-Duvaz, Dan, Zambon, Alfonso, Davies, Lawrence, Whittaker, Steven, Saturno, Grazia, Viros, Amaya, Pedersen, Malin, Suijkerbuijk, Bart M.J.M., Menard, Delphine, McLeary, Robert, Johnson, Louise, Fish, Laura, Ejiama, Sarah, Sanchez-Laorden, Berta, Hohloch, Juliane, Carragher, Neil, Macleod, Kenneth, Ashton, Garry, Marusiak, Anna A., Fusi, Alberto, Brognard, John, Frame, Margaret, Lorigan, Paul, Marais, Richard, Springer, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297292/
https://www.ncbi.nlm.nih.gov/pubmed/25500121
http://dx.doi.org/10.1016/j.ccell.2014.11.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297292/
https://www.ncbi.nlm.nih.gov/pubmed/25500121
http://dx.doi.org/10.1016/j.ccell.2014.11.006

Ejemplares similares